Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:21:30 29/05/2024 am IST			5-day change	1st Jan Change
0.0591 ^USD	+0.17%		+3.68%	-15.69%

2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	CI

Aridis Pharmaceuticals, Inc. Announces New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

January 18, 2023 at 03:00 am IST

Aridis Pharmaceuticals, Inc. announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company's Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients. The KOL event will take place on January 24 at 11 a.m. EST.

AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis (CF) patients. This program is currently in Phase 2a clinical development in CF patients.

Latest news about Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	04/11	CI
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	16/23/16	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer	10/23/10	CI
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index	21/23/21	CI
Sector Update: Health Care Stocks Steady Premarket Tuesday	18/23/18	MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket	18/23/18	MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index	18/23/18	CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours	18/23/18	MT
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	18/23/18	CI
Aridis Pharma Shares Rise 33% After FDA Product Designation for AR-301	12/23/12	DJ
Aridis Pharmaceuticals Gets FDA Product Designation for AR-301	12/23/12	DJ
Aridisâ€™ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAâ€™s Qualified Infectious Diseases Product Designation	12/23/12	CI
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs	20/23/20	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Sector Update: Health Care Stocks Advancing Late Wednesday	01/23/01	MT
Sector Update: Health Care	01/23/01	MT
Top Midday Gainers	31/23/31	MT
Aridis Pharma Shares Double After FDA Clearance to Start AR-301 Pneumonia Study	31/23/31	DJ
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	31/23/31	CI
Aridis Pharmaceuticals Files $3 Million Mixed Securities Registration Statement	23/23/23	MT
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI

Chart Aridis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Companyâs clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ARIDIS PHARMACEUTICALS, INC.	-15.69%	28.33L
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.80%	10TCr
BIONTECH SE	-10.84%	2.27TCr
ARGENX SE	+3.99%	2.18TCr
GENMAB A/S	-10.49%	1.82TCr
WUXI APPTEC CO., LTD.	-41.92%	1.65TCr
BEIGENE, LTD.	-15.11%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+6.62%	1.41TCr
SAREPTA THERAPEUTICS, INC.	+17.53%	1.07TCr

Bio Therapeutic Drugs